Parkman Healthcare Partners LLC Purchases 23,292 Shares of Urogen Pharma $URGN

Key Points

• Parkman Healthcare Partners LLC increased its stake in Urogen Pharma by 6.3% in the first quarter, owning a total of 393,153 shares valued at approximately $4.35 million as of the latest reporting period.
• In the most recent quarter, Urogen Pharma reported a loss of ($1.05) per share, missing analysts' expectations and reflecting a negative return on equity of 97,487.15%.
• Analysts have mixed opinions on Urogen Pharma, with ratings ranging from "Strong Buy" to "Hold" and price targets varying from $16.00 to $36.00, indicating differing sentiments on stock valuation.

Parkman Healthcare Partners LLC boosted its holdings in Urogen Pharma (NASDAQ:URGN - Free Report) by 6.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 393,153 shares of the company's stock after buying an additional 23,292 shares during the period. Parkman Healthcare Partners LLC owned approximately 0.85% of Urogen Pharma worth $4,348,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the business. Lazard Asset Management LLC acquired a new stake in Urogen Pharma during the fourth quarter worth about $67,000. Janus Henderson Group PLC bought a new position in Urogen Pharma during the fourth quarter valued at about $149,000. ProShare Advisors LLC bought a new position in Urogen Pharma during the fourth quarter valued at about $137,000. Rhumbline Advisers increased its stake in Urogen Pharma by 4.3% during the first quarter. Rhumbline Advisers now owns 53,466 shares of the company's stock valued at $591,000 after acquiring an additional 2,196 shares during the period. Finally, Nuveen LLC bought a new position in Urogen Pharma during the first quarter valued at about $1,028,000. 91.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

URGN has been the topic of several research reports. Oppenheimer set a $31.00 price target on Urogen Pharma and gave the company a "buy" rating in a research note on Friday, June 13th. Piper Sandler initiated coverage on Urogen Pharma in a research note on Monday, August 18th. They set an "overweight" rating and a $36.00 price target on the stock. D. Boral Capital restated a "buy" rating and set a $25.00 price target on shares of Urogen Pharma in a research note on Tuesday, August 5th. Guggenheim restated a "buy" rating and set a $30.00 price target (up from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. Finally, HC Wainwright lowered their price target on Urogen Pharma from $50.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $32.00.

Insider Buying and Selling

In related news, General Counsel Jason Drew Smith sold 7,522 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $19.14, for a total value of $143,971.08. Following the completion of the sale, the general counsel owned 41,492 shares of the company's stock, valued at $794,156.88. This trade represents a 15.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Mark Schoenberg sold 10,000 shares of the business's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $17.69, for a total value of $176,900.00. Following the sale, the insider owned 148,229 shares of the company's stock, valued at approximately $2,622,171.01. The trade was a 6.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold 25,062 shares of company stock valued at $465,115 in the last quarter. 4.70% of the stock is currently owned by corporate insiders.

Urogen Pharma Trading Down 3.4%

URGN stock traded down $0.73 during trading on Tuesday, hitting $20.69. The company had a trading volume of 1,406,924 shares, compared to its average volume of 1,045,916. The company has a fifty day moving average price of $17.85 and a two-hundred day moving average price of $12.68. The company has a market cap of $957.12 million, a P/E ratio of -6.23 and a beta of 1.10. Urogen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $21.71.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.23). Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. The company had revenue of $24.22 million during the quarter, compared to analyst estimates of $23.06 million. On average, analysts expect that Urogen Pharma will post -3.12 earnings per share for the current year.

Urogen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.